Revvity, Inc. (RVTY) Down 5.0% — Is It Time to Shed This Weight?
Revvity, Inc. (RVTY) ended Tuesday's session under significant pressure, dropping 4.95% and shedding $5.70 to close at $109.52 on the NYSE. The decline puts the stock within uncomfortable proximity to its 52-week low territory, now sitting approximately 7.4% below its 52-week high of $118.30, a level last reached on January 22, 2026. That high now looks increasingly distant as the stock retreats rather than consolidates, and the session's close offers little technical comfort for investors hoping for stabilization.
Volume told a story of restrained conviction on both sides—693,237 shares changed hands against a 90-day average of roughly 1.38 million, meaning turnover ran at about half the typical pace. The subdued volume prevented the decline from taking on the character of a high-conviction selloff, but it also offered no evidence of meaningful buying support stepping in to absorb the weakness.
Why Revvity, Inc. Price is Moving Lower
Today's roughly 5% decline reflects investor anxiety building ahead of Revvity's Q2 2026 results, compounding a fundamental reset that has been weighing on the stock since May. This is a valuation and sentiment story tied directly to a guidance revision that already meaningfully reset expectations. Analysts had been penciling in adjusted EPS of approximately $1.23 and revenue of around $703 million for Q2, against $1.18 EPS and $720.3 million in the year-ago quarter—a setup that implied revenue declining roughly 2.4% year over year even before the print arrives. As of the time of this writing, actual Q2 results had not been reported, leaving investors to price in uncertainty rather than react to a confirmed outcome.
The deeper wound came from Q1 2026 results released on May 5. While adjusted EPS came in at $1.06 against a $1.02 consensus and revenue of $711.1 million exceeded the roughly $704 million expectation, management simultaneously cut full-year pro-forma adjusted EPS guidance to $5.20–$5.30 from the prior $5.35–$5.45 range. Revenue guidance was slashed even more sharply, dropping to $2.81billion–$2.84 billion from $2.96 billion–$2.99 billion—a reduction driven in part by the planned divestiture of its China immunodiagnostics business. Adjusted operating margin deteriorating to 23.6% from 25.6% a year earlier added another layer of concern, signaling that cost pressures are eroding profitability even as the top line holds relatively steady.
The valuation picture compounds the difficulty. As of early July, the average analyst price target stood at approximately $108.92—which means the stock is now trading fractionally above that consensus target, leaving virtually no implied upside from current Street estimates. That dynamic strips away a key source of potential support: when a stock is already trading at or through consensus targets heading into an earnings print with a lowered full-year outlook, the asymmetry of risk tilts meaningfully to the downside. Investors have little margin for a negative surprise.
What is the Revvity, Inc. Rating - Should I Sell?
Weiss Ratings assigns RVTY a C- rating. Current recommendation is Hold. That C- reflects a stock navigating a genuinely difficult stretch—one where the fundamentals have deteriorated enough to warrant caution, but where the picture has not deteriorated to the point that an outright exit is clearly warranted. The rating sits at the lower boundary of the Hold range, and the sub-index breakdown illustrates exactly why.
Revenue growth of 6.97% and a profit margin of 8.25% are modest figures for a life sciences tools and diagnostics business competing against well-resourced peers, and neither is strong enough to offset the concerns flagged elsewhere in the ratings model. ROE of 3.23% earns the Fair Efficiency Index—a low return for a company operating in a sector where capital intensity is high and the competitive moat should theoretically command stronger earnings on equity. For a business that pivoted toward higher-value diagnostics and life sciences instrumentation after divesting its legacy segments, a sub-4% ROE suggests the transition has yet to translate into the capital efficiency the restructured portfolio should eventually support.
The Solvency Index stands out as the single clear bright spot, registering Excellent—indicating that Revvity's balance sheet is on solid footing and near-term liquidity risk is not a pressing concern. That matters in a period of earnings uncertainty, as it means the company retains financial flexibility without being forced into dilutive actions. But the Weak Growth Index, Weak Total Return Index, and Weak Volatility Index collectively paint a cautionary picture: growth has stalled relative to expectations, total returns have disappointed, and price swings remain elevated—a combination that makes the stock difficult to own with confidence.
Within the Health Care sector, Revvity ranks a notch below AbbVie Inc. (ABBV, C), Merck & Co., Inc. (MRK, C), Thermo Fisher Scientific Inc. (TMO, C), and Pfizer Inc. (PFE, C), all of which carry straight C ratings. Danaher Corporation (DHR, C-) sits at the same level as RVTY, a relevant comparison given Danaher's similar exposure to life sciences instrumentation and tools markets. Neither stock has escaped the sector-wide pressure on diagnostics and research-tools demand, but the shared C- among two of the group's closest business analogs underscores that the challenges here are not purely company-specific.
About Revvity, Inc.
Revvity, Inc. (RVTY) is a Health Care company focused on delivering instruments, reagents, software, and services that enable scientific discovery, diagnostics, and applied research workflows. Formerly known as PerkinElmer, the company rebranded to Revvity in 2023 following the divestiture of its industrial and applied businesses, marking a deliberate pivot toward higher-growth end markets in life sciences and precision diagnostics. That strategic repositioning placed the company squarely in the orbit of pharmaceutical, biotech, academic, and clinical customers who rely on its platforms for everything from genetic screening to immunoassay development.
The company's portfolio is organized around two primary segments. Its Life Sciences segment provides analytical instruments, reagents, and informatics solutions aimed at drug discovery, genomics, and cellular biology research—tools that sit at critical workflow junctures where researchers cannot afford performance variability. Its Diagnostics segment supplies immunoassay and molecular testing systems deployed in newborn screening programs, reproductive health testing, and applied genomics, giving Revvity a meaningful presence in population-level health screening programs across multiple geographies.
Revvity benefits from a significant installed base of instruments in laboratories around the world, creating a recurring revenue stream tied to consumables, reagents, and service contracts that provides some insulation from capital spending cycles. Its intellectual property in detection technologies and its long-standing relationships with national health screening programs represent meaningful competitive advantages that take years to cultivate. The planned divestiture of its China immunodiagnostics business reflects an ongoing effort to sharpen the portfolio's focus on markets where Revvity can sustain premium positioning and stronger margins over the long term.
Investor Outlook
Revvity, Inc. (RVTY) carries a Weiss Rating of C- (Hold), and with the stock trading near the average analyst price target and Q2 2026 results yet to be reported against a backdrop of already-lowered full-year guidance, the near-term risk-reward remains asymmetric. Investors should watch closely for the Q2 print—specifically whether actual EPS and revenue come in relative to the $1.23 and $703 million estimates, and whether management offers any revision to the $2.81 billion–$2.84 billion full-year revenue range. Any further guidance reduction or margin deterioration below the Q1's 23.6% adjusted operating margin would likely put additional pressure on a stock with little valuation cushion remaining. See full rankings of all C--rated Health Care stocks inside the Weiss Stock Screener.
--